FDA Expands Empaveli Approval to Treat Rare Kidney Diseases, Offering New Hope
The U.S. Food and Drug Administration (FDA) has broadened the approval of Empaveli (pegcetacoplan), a complement inhibitor, to include the treatment of two rare and serious kidney diseases: C3 glomerulopathy…